Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics

Pacific Biosciences of California, Inc. (PACB): $3.75

0.03 (+0.81%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

PACB Price/Volume Stats

Current price $3.75 52-week high $14.55
Prev. close $3.72 52-week low $3.45
Day low $3.68 Volume 6,566,400
Day high $3.89 Avg. volume 8,815,147
50-day MA $5.41 Dividend yield N/A
200-day MA $8.81 Market Cap 1.00B

PACB Stock Price Chart Interactive Chart >

PACB POWR Grades

  • PACB scores best on the Growth dimension, with a Growth rank ahead of 65.2% of US stocks.
  • PACB's strongest trending metric is Quality; it's been moving up over the last 26 weeks.
  • PACB's current lowest rank is in the Stability metric (where it is better than 9.08% of US stocks).

PACB Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PACB is 0.22 -- better than just 18.05% of US stocks.
  • PACB's price/sales ratio is 14.53; that's higher than the P/S ratio of 92.57% of US stocks.
  • As for revenue growth, note that PACB's revenue has grown 23.76% over the past 12 months; that beats the revenue growth of 80.39% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PACIFIC BIOSCIENCES OF CALIFORNIA INC are VERU, ROIV, AKTS, GANX, and IPWR.
  • Visit PACB's SEC page to see the company's official filings. To visit the company's web site, go to www.pacb.com.

PACB Valuation Summary

  • In comparison to the median Healthcare stock, PACB's price/sales ratio is 604.55% higher, now standing at 15.5.
  • PACB's price/earnings ratio has moved down 1.4 over the prior 160 months.

Below are key valuation metrics over time for PACB.

Stock Date P/S P/B P/E EV/EBIT
PACB 2023-12-29 15.5 3.4 -8.5 -10.4
PACB 2023-12-28 16.3 3.6 -9.0 -10.9
PACB 2023-12-27 15.9 3.5 -8.7 -10.6
PACB 2023-12-26 16.2 3.6 -8.9 -10.8
PACB 2023-12-22 15.9 3.5 -8.7 -10.6
PACB 2023-12-21 15.6 3.5 -8.6 -10.5

PACB Growth Metrics

    Its 2 year price growth rate is now at 80.53%.
  • Its 4 year net income to common stockholders growth rate is now at 33.39%.
  • Its 3 year revenue growth rate is now at 77.95%.
Over the past 15 months, PACB's revenue has gone up $31,145,000.

The table below shows PACB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 136.97 -234.353 -299.193
2022-06-30 139.546 -211.956 -205.68
2022-03-31 134.689 -167.105 -175.287
2021-12-31 130.513 -111.18 -181.223
2021-09-30 121.63 -93.735 -36.959
2021-06-30 105.825 -70.887 -77.209

PACB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PACB has a Quality Grade of C, ranking ahead of 52.82% of graded US stocks.
  • PACB's asset turnover comes in at 0.132 -- ranking 67th of 75 Measuring and Control Equipment stocks.
  • TMO, PKI, and PRPO are the stocks whose asset turnover ratios are most correlated with PACB.

The table below shows PACB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.132 0.427 -0.085
2021-03-31 0.169 0.412 -0.129
2020-12-31 0.271 0.413 0.185
2020-09-30 0.355 0.428 -0.409
2020-06-30 0.445 0.411 -0.473
2020-03-31 0.515 0.410 -0.412

PACB Price Target

For more insight on analysts targets of PACB, see our PACB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.75 Average Broker Recommendation 1.6 (Moderate Buy)

Pacific Biosciences of California, Inc. (PACB) Company Bio


Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.


PACB Latest News Stream


Event/Time News Detail
Loading, please wait...

PACB Latest Social Stream


Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about PACIFIC BIOSCIENCES OF CALIFORNIA INC that investors may wish to consider to help them evaluate PACB as an investment opportunity.

PacBio to Present at 42nd Annual J.P. Morgan Healthcare Conference

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 1:30 PM PT (4:30 PM ET) in San Francisco, California.

Yahoo | December 27, 2023

CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?

CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Yahoo | December 27, 2023

Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now

PacBio's (PACB) product development activities raise optimism about the stock.

Yahoo | December 26, 2023

12 Most Promising Gene Editing Stocks According to Hedge Funds

In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds. If you want to skip our take on how the gene editing industry sits right at the top of the global innovation food chain, then you can take a look at the 5 Most Promising […]

Yahoo | December 20, 2023

Investors in Pacific Biosciences of California (NASDAQ:PACB) have unfortunately lost 60% over the last three years

Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) shareholders should be happy to see the share price up 29% in...

Yahoo | December 12, 2023

Read More 'PACB' Stories Here

PACB Price Returns

1-mo -32.68%
3-mo -61.77%
6-mo -55.09%
1-year -61.58%
3-year -87.48%
5-year -48.13%
YTD -61.77%
2023 19.93%
2022 -60.02%
2021 -21.13%
2020 404.67%
2019 -30.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!